Branded Pharma Feels the Pinch from the Inter Partes Review Monster It Helped Create

[...]a patent can be viewed as broader than it would otherwise be in the courts (thereby making it easier to invalidate). A case study in this technique--albeit in a chemical, not a pharmaceutical, context--is the recent Federal Circuit decision in GrafTech Int'l Holdings v. Laird Technologies, Inc., where the appellate court affirmed the PTAB's decision that three GrafTech patents were unpatentable.